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patients ’ ESA response index and the divi-
sion of responses into quintiles. This 
avoided inclusion of transiently hypo-
responsive patients based on conditions 
not immediately apparent to the clinician. 
Our own experience suggests that a period 
of 6 months is needed to detect hypore-
sponsiveness in about 15 % of the hemo-
dialysis population, who remain 
hyporesponsive for that duration. Th eir 
dose of ESA is markedly higher than that 
of sensitive patients, but because of the 
constraints of the  ‘ target ’ range, the same 
mean Hb is attained. Th e importance of 
detecting this subset resides in the eco-
nomic cost of ESA therapy ( Figure 1 ) and 
in opportunities to avoid harm from 
 “ excessive ” ESA dosing to reach the 
desired Hb target. 
 As important as economics is, the issue 
of risk versus benefit when higher Hb 
levels are targeted may be more impor-
tant. If the findings of an association 
between the relative abundance of onco-
statin M fragments and poor response, 
and between cysteine / histidine-rich 1 and 
good response, can be confi rmed in larger 
cohorts of patients, it may allow us to 
actually conduct the randomized control-
led trials necessary to fi nd the best strat-
egy for managing such poorly responsive 
patients. Certainly, this strategy cannot be 
to increase the ESA dose until the same 
Hb level is reached in poor as in better 
responders — that is, equivalent Hb attain-
ment in all quartiles or quintiles of dose. 
Th e ability to periodically determine the 
responsiveness of the patient can only help 
refi ne the use and prevent the misuse of 
ESAs. 
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 Chronic kidney disease (CKD) strongly 
increases patient risk for cardiovascular 
morbidity and mortality. Th is striking dif-
ference in cardiovascular risk between 
CKD patients and the general population 
is not attributable only to increased expo-
sure to the traditional Framingham Study 
risk factors but in addition depends on a 
number of so-called  ‘ novel, ’ uremia-
related risk factors, among which miner-
alization of blood vessels (vascular 
calcifi cation, an ectopic mineralization) 
takes a prominent position. 1 
 Numerous epidemiologic studies have 
found that vascular calcifi cation in CKD 
patients contributes to the increased 
cardiovascular risk in this population, 
and that hyperphosphatemia and hyper-
calcemic episodes are associated with 
the development of uremia-related vas-
cular calcification. The intimate link 
between disturbances of mineral metab-
olism inherent to impaired renal 
 function and the development of both 
renal osteodystrophy and vascular cal-
cifi cation is now broadly captured under 
the term  ‘ chronic kidney disease –
 mineral and bone disorder. ’ 2 
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 From a mechanistic point of view, vas-
cular calcification emerges either as a 
direct mineralization of vascular extracel-
lular matrix, as seen in medial elastic 
lamellae in the absence of inhibitory 
matrix Gla protein (MGP), or as a com-
plex, cell-regulated process. In the latter 
case, disturbances in mineral metabolism 
attributable to renal function impairment 
trigger cellular transdiff erentiation of vas-
cular smooth muscle cells into chondro- / 
osteoblast-like cells, which produce matrix 
vesicles and other mediators of minerali-
zation, including transcription factors and 
growth factors (such as Runx2 / Cbfa1, 
Msx2, Osterix, Sox9, and BMP2) normally 
associated only with skeletal and dental 
cells, as well as downstream, often-
secreted molecular determinants of min-
eralization (such as alkaline phosphatase, 
osteopontin, osteocalcin, bone sialopro-
tein, and MGP). The presence of cells 
capable of regulating mineralization in a 
uremic milieu — where calcium and phos-
phate, the ions necessary for mineral for-
mation, are abundant, and a number of 
circulating and local mineralization 
 inhibitors, such as MGP, fetuin-A, and 
pyrophosphate, are decreased — clearly 
sets the stage for the development of vas-
cular calcifi cation. 
 O ’ Neill and colleagues 3 (this issue) 
report that administration of the miner-
alization inhibitor pyrophosphate to ure-
mic rats prevents or reduces the 
development of ectopic calcifi cation in 
blood vessels, without overtly aff ecting 
skeletal mineralization and without cal-
cium pyrophosphate deposition disease in 
joints. In rats made uremic by administra-
tion of an adenine-rich diet, intraperito-
neal administration of pyrophosphate 
(which is rapidly hydrolyzed if given 
orally) decreased the extent of calcium 
(mineral) deposition in calcifi ed vessels, 
but not the incidence of vascular calcifi ca-
tion. When calcitriol was used to induce 
vascular calcifi cation in uremic rats, pyro-
phosphate administration diminished 
both the incidence and the severity of vas-
cular calcifi cation. Th ese fi ndings confi rm 
the importance of the phosphate – pyro-
phosphate ratio in the development of 
vascular calcifi cation and hint at a promis-
ing new pyrophosphate treatment 
approach for uremic CKD patients (or for 
any other patient group prone to ectopic 
mineralization, for that matter) disposed 
to vascular calcifi cation. 
 Whereas MGP ’ s central, non-redundant 
role as a locally produced inhibitor of 
extracellular matrix mineralization in 
medial arterial calcification has been 
determined in mice, 4 other types of vas-
cular calcifi cation are seemingly highly 
complex, involving a plethora of determi-
nants acting at both the cellular and the 
extracellular level. Th ese typically involve 
infl ammation, cell necrosis with necrotic 
debris, apoptotic vesicles, matrix vesicles, 
lipid accumulation, and a reprogramming 
of vascular smooth muscle cells into the 
chondro- / osteogenic pathway, resulting 
in the appearance of mineralized-tissue 
gene expression profi les in calcifi ed ves-
sels. Once a calcifi cation focus is nucle-
ated, further mineral deposition within it 
can be regulated by factors and secreted 
proteins that have been most extensively 
examined in studies on bone. Most 
prominent among these studies is work 
repeatedly describing upregulation of 
osteopontin (OPN) at these sites, where it 
colocalizes with mineral in the vessel wall 
and is thought to act as a reactionary mol-
ecule limiting further ectopic mineraliza-
tion. Mice lacking both MGP and OPN 
show accelerated death by vascular rup-
ture and increased deposition of vascular 
mineral as compared with mice defi cient 
in MGP alone. 4 
 While pyrophosphate ’ s inhibitory 
eff ects on mineralization have long been 
known, as has the fact that these eff ects 
can be removed by degradation of pyro-
phosphate by the enzyme alkaline phos-
phatase, only in recent years has an 
understanding been achieved of how 
pyrophosphate is handled by cells to infl u-
ence the phosphate – pyrophosphate ratio. 
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 Figure 1  |  Schematic representation of the central role of tissue-nonspecific alkaline 
phosphatase in determining the ratio of phosphate to pyrophosphate  and the balance 
between mineralization induction and inhibition. In vascular cells, low tissue-nonspecific 
alkaline phosphatase (TNAP) activity results in an abundant inorganic pyrophosphate (PP i ) level, 
which inhibits extracellular matrix mineralization, whereas in bone cells, high TNAP activity 
removes PP i , thus allowing the mineralization process to proceed. In uremia, pathologic TNAP 
upregulation that degrades inhibitory PP i is one of the factors contributing to vascular calcification. 
P i , inorganic phosphate. 
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In studies using primarily transgenic 
mice, a better understanding has now 
emerged of how pyrophosphate is 
 transported extracellularly across the 
plasma membrane by the transporter 
ANK, or generated from nucleotides out-
side the cell at the level of the plasma 
membrane by ENPP1, then to be degraded 
by plasma membrane-resident tissue-
nonspecific alkaline phosphatase 
(TNAP). 5 Such processing of substrate 
pyrophosphate by TNAP simultaneously 
removes inhibitory pyrophosphate while 
generating two phosphate ions — both of 
which tip the phosphate – pyrophosphate 
ratio in favor of mineralization. 
 Bisphosphonates — nonhydrolyzable ana-
logs of pyrophosphate widely used for the 
treatment of osteoporosis because of their 
toxicity to bone-resorbing osteoclasts —
 have been reported to prevent vascular 
calcification in both experimental and 
clinical studies. 6,7 At higher doses, bisphos-
phonates — like pyrophosphate — physico-
chemically inhibit mineral deposition, but 
their therapeutic use depends on inhibition 
of osteoclast-mediated bone resorption that 
occurs at low doses that do not interfere 
with the mineralization process. 
 Th e clinical usefulness of bisphospho-
nates to treat vascular calcification is 
limited, however, because the high doses 
that would be required to inhibit calcifi -
cation in turn would adversely affect 
skeletal biology, and because bisphos-
phonates are eliminated from the body 
by renal clearance. Th us, most nephrolo-
gists would refrain from giving bisphos-
phonates to their CKD patients in view 
of the clearance problems and long half-
life of these products on the one hand, 
and also because of the danger of induc-
ing adynamic bone disease by oversup-
pression of bone turnover. Indeed, 
adynamic bone disease is associated with 
an increased risk for vascular calcifi ca-
tion, probably because adynamic bone 
cannot buff er excess calcium and phos-
phate in cases of hyperphosphatemia or 
hypercalcemic episodes. 8 
 Although O ’ Neill and colleagues 3 did 
not observe any eff ect of pyrophosphate 
on certain commonly measured bone 
 histology parameters, the potential 
adverse eff ects of pyrophosphate admin-
istration on bone need to be investigated 
more closely. Th e follow-up in this exper-
imental study was limited to 4 weeks, and 
bone metabolism in rats and humans 
shows important diff erences, such as dif-
ferent growth and metabolic parameters 
that include a larger restoration capacity 
and buff er capacity for dealing with fl uc-
tuations in calcium and phosphorus load 
in growing bone. Other characteristics of 
bone, such as mineral quantity and qual-
ity and its biomechanical properties, need 
to be assessed aft er pyrophosphate treat-
ment. Th e lack of overt changes in some 
bone mineralization measurements is 
thought to be attributable to the abundant 
TNAP enzyme expressed by bone cells, 
which in cleaving pyrophosphate would 
limit the inhibitory eff ect of pyrophos-
phate on bone mineralization. Lesser pro-
duction of TNAP by cells in the vessel 
wall, together with high local levels of cir-
culating pyrophosphate arising from the 
systemic administration route and diff us-
ing into the vessel wall, may tip the 
local phosphate – pyrophosphate balance 
toward inhibition of mineral deposition 
( Figure 1 ). Future studies on pyrophos-
phate treatment will require careful exam-
ination of pyrophosphate-handling gene 
expression (for example, ANK, ENPP1, 
and TNAP) in aff ected tissues, the eff ects 
of dosing and administration route, and 
of intermittent pyrophosphate treatment, 
always with attention being given to 
eff ects on bone mineralization and the 
possibility of calcium pyrophosphate 
deposition disease in joints. 
 Th is study — like all experimental stud-
ies on uremia-related vascular calcifi ca-
tion — inherently suffers from the 
limitations of the available animal mod-
els themselves. Feeding animals an ade-
nine-rich diet reproducibly induces renal 
function impairment, but the fraction of 
animals in which vascular calcifi cation 
occurs is variable, even when the animals 
are maintained on a calcification-
promoting, low-protein diet. Although 
this variable incidence was circumvented 
experimentally by administration of 
supraphysiologic doses of calcitriol 
to induce consistent vascular calcifi ca-
tion, this animal model of calcifi cation 
may be too strong an induction model, 
and less representative of the situation 
in humans. 
 Pyrophosphate is a very short-lived 
molecule, with a half-life in rats of slightly 
more than 30  minutes, although the 
authors used various means to prolong 
the adsorption of pyrophosphate aft er 
peritoneal injection. Thus, it is as yet 
unclear whether this molecule is a suita-
ble long-term treatment option for vas-
cular calcification in humans. More 
research is needed to investigate the 
relationship between the short systemic 
half-life of this molecule and its eff ects on 
the local  pyrophosphate concentration in 
tissue, particularly in the vascular wall. If 
the  tissue half-life of this molecule sur-
passes its systemic half-life by multiple 
orders of  magnitude, long-term adminis-
tration of pyrophosphate may cause this 
molecule to accumulate extracellularly in 
the tissue, potentially leading to long-
term consequences for bone formation 
and mineralization. 
 Th e short half-life of pyrophosphate 
also triggers the question of the optimal 
route for administration. Whereas it may 
be feasible to expose peritoneal dialysis 
patients continuously to pyrophosphate, 
for dialysis patients or CKD patients 
not yet on dialysis, frequent and continu-
ous exposure to pyrophosphate seems 
less feasible. 
 Vascular calcifi cation is now well estab-
lished as a surrogate marker of cardio-
vascular risk in CKD patients. However, 
it remains to be determined whether 
inhibition of vascular calcifi cation is suf-
fi cient to halt the multifactorial patho-
genetic mechanisms that lead to arterial 
stiff ening, calcifi cation, and increased 
cardiovascular mortality risk. And, 
although a number of interventions have 
been shown in either animals or patients 
to inhibit the development of vascular 
calcifi cation, there is a paucity of evi-
dence that interventions can reverse 
established calcifi cations. When renal 
function is restored by transplantation, 
this seems to halt the progression of cal-
cifi cation but does not reverse the calci-
fi cation pro cess, 9 although experimental 
studies yield confl icting results. Taking 
into account the highly insoluble nature 
of the depo sited bioapatite, regression of 
vascular calcifi cation likely would have 
to invoke an active, cell-regulated resorp-
tion pro cess that parallels mechanisms of 
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bone resorption by lowering extracellular 
pH. 10 It thus seems unlikely that pyro-
phosphate would have a role in any vas-
cular mineral regression process of 
established calci fi cations, especially when 
pyrophosphate additionally slows min-
eral dissolution. 
 In summary, O ’ Neill and colleagues 3 
present convincing experimental evidence 
that systemic administration of pyro-
phosphate to uremic rats inhibits the 
development of uremia-related vascular 
calcifi cation, without apparent adverse 
eff ects on bone mineralization. 
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